We are live on ! Find out more
AMRX icon

Amneal Pharmaceuticals
AMRX

277 hedge funds and large institutions have $1.95B invested in Amneal Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 57 funds opening new positions, 100 increasing their positions, 80 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

611% more call options, than puts

Call options by funds: $7.01M | Put options by funds: $985K

128% more first-time investments, than exits

New positions opened: 57 | Existing positions closed: 25

29% more capital invested

Capital invested by funds: $1.51B → $1.95B (+$437M)

25% more repeat investments, than reductions

Existing positions increased: 100 | Existing positions reduced: 80

12% more funds holding

Funds holding: 248 → 277 (+29)

1.15% more ownership

Funds ownership: 48.01% → 49.17% (+1.2%)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

Holders
277
Holders Change
+29
Holders Change %
+11.69%
% of All Funds
3.37%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
57
Increased
100
Reduced
80
Closed
25
Calls
$7.01M
Puts
$985K
Net Calls
+$6.02M
Net Calls Change
-$921K

Top Buyers

1
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$18.4M
2
Morgan Stanley
Morgan Stanley
New York
+$15M
3
PHS
PFM Health Sciences
California
+$12.7M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$12.5M
5
PCM
Penn Capital Management
Pennsylvania
+$11.5M

Top Sellers

1
NCM
Nantahala Capital Management
Connecticut
-$20.3M
2
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$17.5M
3
Deutsche Bank
Deutsche Bank
Germany
-$9.56M
4
Prudential Financial
Prudential Financial
New Jersey
-$8.48M
5
Walleye Capital
Walleye Capital
New York
-$8M
Name Holding Trade Value Shares
Change 		Change in
Stake
Jones Financial Companies
251
Jones Financial Companies
Missouri
$1.92K +$1.17K +102 +204%
CFB
252
Cullen/Frost Bankers
Texas
$1.9K – – –
AAG
253
Armstrong Advisory Group
Massachusetts
$1.89K – – –
PMAM
254
Picton Mahoney Asset Management
Ontario, Canada
$1.68K – – –
PA
255
Parallel Advisors
California
$1.65K – – –
GFA
256
Godfrey Financial Associates
New York
$1.65K +$1.5K +131 New
SS
257
SBI Securities
Japan
$1.59K +$984 +86 +215%
JWA
258
JFS Wealth Advisors
Pennsylvania
$1.31K +$389 +34 +49%
KFAS
259
Keating Financial Advisory Services
Kansas
$882 +$801 +70 New
PFBT
260
Parkside Financial Bank & Trust
Missouri
$832 – – –
NSIM
261
North Star Investment Management
Illinois
$756 – – –
ZBNA
262
Zions Bancorporation, National Association
Utah
$592 +$538 +47 New
CPG
263
Cornerstone Planning Group
New Jersey
$558 – – –
TWD
264
True Wealth Design
Ohio
$517 – – –
SVCP
265
Silicon Valley Capital Partners
California
$378 – – –
DPW
266
DiNuzzo Private Wealth
Pennsylvania
$315 +$34 +3 +14%
FHA
267
Flagship Harbor Advisors
Massachusetts
$315 +$286 +25 New
APW
268
Atlantic Private Wealth
North Carolina
$252 +$229 +20 New
SIC
269
SJS Investment Consulting
Ohio
$215 – – –
RWM
270
Rialto Wealth Management
New York
$177 – – –
HIA
271
HFM Investment Advisors
New Jersey
$114 – – –
BHWM
272
Bay Harbor Wealth Management
Maryland
$113 -$57 -5 -36%
LFG
273
Larson Financial Group
Missouri
$88 +$80 +7 New
CIAM
274
Caitong International Asset Management
Hong Kong
$63 +$57 +5 New
DF
275
Dunhill Financial
United Kingdom
$38 +$34 +3 New
8 9 10
11
12

AMRX Hedge Fund Activity: Q4 2025 in Review

277 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Amneal Pharmaceuticals (AMRX) for Q4 2025, worth a combined $1.95B — up 29% from $1.51B a quarter earlier.

Buyers outnumbered sellers: 57 funds opened new AMRX positions and 25 closed out — a net gain of 32 holders — while 100 added to existing stakes and 80 trimmed.

The largest buyer was Assenagon Asset Management, adding an estimated $18.4M. The largest seller was Nantahala Capital Management, cutting an estimated $20.3M.

  • 277 institutional investors held Amneal Pharmaceuticals (AMRX) as of Q4 2025, up from 248 in Q3 2025.
  • Funds reported $1.95B of Amneal Pharmaceuticals stock for Q4 2025, up 29% quarter-over-quarter.
  • 57 funds opened new Amneal Pharmaceuticals positions in Q4 2025 and 25 closed out, a net change of +32 holders.
  • The largest Amneal Pharmaceuticals buyer in Q4 2025 was Assenagon Asset Management, an estimated $18.4M added.
  • The largest Amneal Pharmaceuticals seller in Q4 2025 was Nantahala Capital Management, an estimated $20.3M sold.

Based on aggregated 13F filings for Q4 2025.